Nuvation Bio to Present at the Cantor Global Healthcare Conference

NEW YORK--(BUSINESS WIRE)-- Nuvation Bio Inc. (NYSE: NUVB), a late clinical-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced that David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio, will present at the Cantor Global Healthcare Conference in New York, NY on Thursday, September 19, 2024, at 9:45 a.m. E.T.

A live webcast of the presentation will be available on the Nuvation Bio website at https://investors.nuvationbio.com/investors/. An archived recording will be available for 90 days following the event.

About Nuvation Bio

Nuvation Bio is a late clinical-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel product candidates. Nuvation Bio’s portfolio of development candidates includes taletrectinib (ROS1), safusidenib (mIDH1), NUV-1511 (DDC), and NUV-868 (BET). Nuvation Bio was founded in 2018 by biopharma industry veteran David Hung, M.D., who previously founded Medivation, Inc., which brought to patients one of the world’s leading prostate cancer medicines. Nuvation Bio has offices in New York, San Francisco, Boston, and Shanghai. For more information, please visit www.nuvationbio.com and https://www.linkedin.com/company/nuvationbio/.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240909328377/en/

Nuvation Bio Investor Contact:
[email protected]

Nuvation Bio Media Contact:
[email protected]

Source: Nuvation Bio

You May Also Be Interested In

• Doha Debates Holds Toronto Town Hall on Football, Money and Fandom
• BZI® and Its Affiliate VISCO® Receive the 2026 Utah Business Fast 50 Award
• Penguin Solutions to Showcase AI Infrastructure and Memory Solutions at AI Infra Summit 2026